CanSino Biologics

Exploring New Collaborative Opportunities! The Indonesia-China Healthcare and Biotech Investment Forum Successfully Held

Retrieved on: 
Monday, July 31, 2023
Partnership, Medical device, Health care, Speech, BGI Group, Chinese Industrial Cooperatives, BeiGene, Kimia Farma, BGI, Shangri-La Hotels and Resorts, Technology policy, Genomics, CanSino Biologics, Global Health, Ministry, Republic, Diplomatic mission, Legislation on Chinese Indonesians, KIKT, Legend Holdings, Tsinghua University, International business, Ecosystem, Ministry of Health (Indonesia), Policy, Commerce, Management, Pharmaceutical industry, China–Indonesia relations, Health

A total of 120 people, including Indonesian government officials, scholars, business people and leading Chinese healthcare companies, attended the event to jointly discuss the direction and opportunities for the development of healthcare and biotech in China and Indonesia.

Key Points: 
  • A total of 120 people, including Indonesian government officials, scholars, business people and leading Chinese healthcare companies, attended the event to jointly discuss the direction and opportunities for the development of healthcare and biotech in China and Indonesia.
  • The forum was chaired by Mr. Jafar WANG, Co-Chief Investment Officer of Legend Capital, who mentioned Legend Capital's latest "Ecosystem plus" strategy in healthcare, and hoped to collaborate with the excellent healthcare enterprises in China and Indonesia to build an open, innovative, and international ecosystem through this forum.
  • Mr. Garibaldi Thohir, Chairman of Indonesia Chamber of Commerce and Industry Bilateral Committee of China (KIKT), Mr. H.E.
  • The Minister of Health Indonesia, Budi Gunadi Sadikin, delivered a keynote speech on "Healthcare Policy and Planning in Indonesia".

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023
Venus, Cloud, Roborock, Forbes China Celebrity 100, Female, Qiming Venture Partners, Midas List, Gan, CYG, Gold, Investment, CanSino Biologics, Mobile robot, T&C, VC, WeRide, Duane, Unisound, Pharmaceutical industry

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023
Venus, Cloud, Roborock, Forbes China Celebrity 100, Female, Qiming Venture Partners, Midas List, Gan, CYG, Gold, Investment, CanSino Biologics, Mobile robot, T&C, VC, WeRide, Duane, Unisound, Pharmaceutical industry

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Retrieved on: 
Friday, April 14, 2023
Vaccine, Retina, Medicine, Schepens Eye Research Institute, CEP290, LCA, Cohort, CMC, Clinical trial, Retinitis pigmentosa, CanSino Biologics, Voretigene neparvovec, Doctor of Philosophy, RP, NR2E3, Development, Patient, Webcast, RHO, Leber congenital amaurosis, Safety, Pharmaceutical industry, Toy, Rhodopsin

“It is very gratifying to see these positive preliminary results from our novel modifier gene therapy approach,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.

Key Points: 
  • “It is very gratifying to see these positive preliminary results from our novel modifier gene therapy approach,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • A total of 18 RP subjects have been enrolled in this study—10 subjects in the dose escalation and 8 subjects in the expansion phase, respectively.
  • We further expanded this Phase1/2 trial to enroll LCA patients with CEP290 gene mutation and pediatric patients with NR2E3, RHO and CEP290 mutations.
  • CanSinoBIO, Ocugen’s strategic partner, provided all CMC development and clinical supplies for the Phase 1/2 trial of OCU400.

CGTN: Understanding China's whole-process people's democracy at Two Sessions

Retrieved on: 
Thursday, March 2, 2023
Tao, Human, Safety, Two Sessions, Democracy, Congress, National Committee of the Chinese Agricultural, Forestry and Water Conservancy Workers' Union, CPC, National People's Congress, Politics, Communist party, Conference, NPC, Chinese People's Political Consultative Conference, Civil code, COVID-19, Committee, Hoxhaism, Environment, CanSino Biologics, Social science, Government, National Committee, Civil Code of the People's Republic of China, CPPCC, Natural Resources, Management, Vaccine

According to Chinese President Xi Jinping, China's whole-process people's democracy "is a democracy that covers all aspects of the democratic process and all sectors of society.

Key Points: 
  • According to Chinese President Xi Jinping, China's whole-process people's democracy "is a democracy that covers all aspects of the democratic process and all sectors of society.
  • It is a socialist democracy to the broadest extent, of the truest nature, and to the greatest effect."
  • Former Tunisian Foreign Minister Ahmed Ounaies said democracy practiced in China is "honest, pragmatic and without showmanship."
  • From President Xi's perspective, "Democracy is not an ornament for display, but an instrument for addressing the issues that concern the people."

CGTN: Understanding China's whole-process people's democracy at Two Sessions

Retrieved on: 
Thursday, March 2, 2023
Tao, Human, Safety, Two Sessions, Democracy, Congress, National Committee of the Chinese Agricultural, Forestry and Water Conservancy Workers' Union, CPC, National People's Congress, Politics, Communist party, Conference, NPC, Chinese People's Political Consultative Conference, Civil code, COVID-19, Committee, Hoxhaism, Environment, CanSino Biologics, Social science, Government, National Committee, Civil Code of the People's Republic of China, CPPCC, Natural Resources, Management, Vaccine

According to Chinese President Xi Jinping, China's whole-process people's democracy "is a democracy that covers all aspects of the democratic process and all sectors of society.

Key Points: 
  • According to Chinese President Xi Jinping, China's whole-process people's democracy "is a democracy that covers all aspects of the democratic process and all sectors of society.
  • It is a socialist democracy to the broadest extent, of the truest nature, and to the greatest effect."
  • Former Tunisian Foreign Minister Ahmed Ounaies said democracy practiced in China is "honest, pragmatic and without showmanship."
  • From President Xi's perspective, "Democracy is not an ornament for display, but an instrument for addressing the issues that concern the people."

Brenus Pharma Announces its Strategic Committee Supporting & Ensuring Its Value-creating Strategic Plan

Retrieved on: 
Wednesday, March 1, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, LEEM, CDMO, Strategy, Society, Trust, HEC Paris, Doctor, Immune system, GE HealthCare, MBA, CSL Vifor, Paris, Non-executive director, Patient, CanSino Biologics, STC, Doctor of Pharmacy, CSO, Roche, Education, Fine chemical, Management, Pharmaceutical industry, Vaccine, Takeda

BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.

Key Points: 
  • BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.
  • Pierre MORGON (Pharm D, LL.M, MBA): CEO, MRGN Advisors ; Executive VP, CanSino Biologics; Board chairman and non-Executive director, several biotech.
  • “We are delighted to have top renowned healthcare industry executives at our side to challenge and support our strategic plan and are thankful for their trust.
  • Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on: 
Thursday, December 15, 2022
Pfizer, Vaccination, United Arab Emirates, Transport, Omicron, Sinopec, Sinovac Biotech, Research, CanSino Biologics, Immunization, Wellcome Trust, World Health Organization, COVID-19, Vaccine, News, WHO, Safety, COVID-19 vaccine, COVAX, Risk, Pharmaceutical industry, Animal, China National Pharmaceutical Group

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points: 
  • In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
  • Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
  • As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
  • It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on: 
Thursday, December 15, 2022
Pfizer, Vaccination, United Arab Emirates, Transport, Omicron, Sinopec, Sinovac Biotech, Research, CanSino Biologics, Immunization, Wellcome Trust, World Health Organization, COVID-19, Vaccine, News, WHO, Safety, COVID-19 vaccine, COVAX, Risk, Pharmaceutical industry, Animal, China National Pharmaceutical Group

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points: 
  • In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
  • Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
  • As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
  • It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.

Retrieved on: 
Thursday, November 24, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Safety, Public health, Convidecia, VLP, Pain, International Society, CanSino Biologics, National Medical Products Administration, Research, Ageing, Tidal volume, Multimedia, Noble gas, Atmosphere of Earth, Chronic obstructive pulmonary disease, COVID-19, Partnership, Severe acute respiratory syndrome coronavirus 2, McGrath, Adenoviridae, Vaccine, Nassar Ikram, WHO, News, Enterprise Ireland, Mechanical, Mechanical ventilation, Vaccination, Use, Effect, Growth, DOI, Diagnosis, Inhalation, COPD, Medtech, Ventilation, Patient, Global Initiative, HKEX, McLoughlin, SSE, COVID19, Pharmaceutical industry, Medical device, Lancet, Medicine

This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.

Key Points: 
  • This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.
  • 2,3
    Further clinical trials of the inhaled vaccine are progressing in Asia and Latin America to support other country approvals for this innovative technology.
  • John Power, Aerogen CEO & Founder said The world has an urgent need for an effective, low-cost, globally scalable, and globally accessible solution to mass vaccination.
  • We are delighted with the news of approval and public rollout in China and look forward to further approval of inhaled vaccines around the world.